The invention relates to a multilayer flexible material (of a tape type) which can be applied and adhere onto a surface to modify its properties. Particularly, an antibacterial and/or antiviral multilayers material comprising a tie binding layer with at least one adhesive face arranged to be fixed on any suitable surface and an active treatment layer arranged on the face of the tie binding layer opposite to adhesive face, said treatment layer comprising anti-bacterial and/or anti-viral agents. The invention is also related to an associated application method and specific uses.

The present invention relates to an ophthalmic pharmaceutical composition comprising a combination of fluoroquinolone antibacterial agent and an anti-inflammatory agent along with a complexing agent and water. The composition is having a pH between 4 and 8. The present invention also relates to the methods of making an ophthalmic pharmaceutical composition and there uses thereof. The present invention also provides a method of treating and/or preventing an ophthalmic condition in a patient.

The present invention relates to an ophthalmic pharmaceutical composition comprising a combination of fluoroquinolone antibacterial agent and an anti-inflammatory agent along with a complexing agent and water. The composition is having a pH between 4 and 8. The present invention also relates to the methods of making an ophthalmic pharmaceutical composition and there uses thereof. The present invention also provides a method of treating and/or preventing an ophthalmic condition in a patient.

The invention provides novel imidazole pyrazole derivatives having the general formula (I), and pharmaceutically acceptable salts thereof, wherein A and R.sup.1-R.sup.7 are as described herein:

##STR00001##

Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds as antibiotics for the treatment or prevention of bacterial infections and resulting diseases.

The invention provides novel imidazole pyrazole derivatives having the general formula (I), and pharmaceutically acceptable salts thereof, wherein A and R.sup.1-R.sup.7 are as described herein:

##STR00001##

Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds as antibiotics for the treatment or prevention of bacterial infections and resulting diseases.

The present invention provides high-complexity defined gut microbial communities capable of achieving substantial engraftment and having stability following human fecal community microbial challenge and methods of producing the same. Also provided are methods of using high-complexity defined gut microbial communities for the treatment of dysbiosis or a pathological condition in an animal.

CB-7 exhibits a weak TLR7 inhibiting effect in normal mice. The present invention provides a novel compound with a stronger TLR7 inhibiting effect than CB-7, a pharmaceutically acceptable salt of said compound, or a prodrug of said compound or salt. The present invention also provides a drug for the prevention or treatment of diseases associated with the activation of TLR7, said drug including the aforementioned TLR7 activation inhibitor.

The present invention is directed to PVP-I formulations having enhanced virucidal activity. The formulations are intended for topical administration for treatment and/or decreased risk of microbial infections in subjects. The formulations include PVP-I and other ingredients selected to enhance the virucidal activity of the formulation over PVP-I alone.

The disclosure relates to thiosulfur containing compositions, in particular propyl-propane thiosulfonate (PTSO) and propyl-propane-thiosulfinate (PTS). Such compositions are useful for treating infection and reducing or degrading biofilms both in vivo and in vitro. In particular, such compositions are useful in the treatment of biofilm-related disorders, including but not limited to mastitis, digital dermatitis, and chronic wound infections.

The present disclosure generally relates to a method for reducing the toxicity of inhaled polymyxins as a therapeutic agent comprising the step of co-administration of an aminoglycoside; a method for improving the aerosolization of an aminoglycoside comprising the step of combination formulation with a polymyxin; and a process for manufacturing a dry powder composition comprising a polymyxin and aminoglycoside. Pharmaceutical compositions and methods of treatment for lung infections are within the scope of this invention.